We show that ZSTK474, a PI3K inhibitor, and trametinib, a MEK inhibitor, synergistically inhibit DIPG cell proliferation in vitro and in vivo, prolonging survival in a genetically engineered mouse DIPG model following CED administration. The gene discussed is MAP2K7; the disease is diffuse intrinsic pontine glioma.